Search

To evaluate the safety and survival outcomes of computed tomography–guided microwave ablation (MWA) for medically inoperable Stage I non–small cell lung cancer (NSCLC) in patients aged ≥70 years. This study was a prospective, single-arm, single-center clinical trial. The MWA clinical trial enrolled patients aged ≥70 years with medically inoperable Stage I NSCLC from January 2021 to October 2021. All patients received biopsy and MWA synchronously with the coaxial technique. The primary endpoints were 1-year overall survival (OS) and progression-free survival (PFS). The secondary endpoint was adverse events. A total of 103 patients were enrolled. Ninety-seven patients were eligible and analyzed. The median age was 75 years (range, 70–91 years). The median diameter of tumors was 16 mm (range, 6–33 mm). Adenocarcinoma (87.6%) was the most common histologic finding. With a median follow-up of 16.0 months, the 1-year OS and PFS rates were 99.0% and 93.7%, respectively. There were no procedure-related deaths in any patient within 30 days after MWA. Most of the adverse events were minor. MWA is an effective and safe treatment for patients aged ≥70 years with medically inoperable Stage I NSCLC. [Display omitted] [ABSTRACT FROM AUTHOR]

Purpose: To evaluate the short-term efficacy and safety of immunotherapy with sintilimab combined with bronchial arterial infusion (BAI) chemotherapy/drug-eluting embolic (DEE) bronchial arterial chemoembolization (BACE) for advanced non-small cell lung cancer (NSCLC).Materials and Methods: Ten patients with advanced NSCLC were treated with sintilimab plus BAI/DEE-BACE between December 2019 and November 2020 and retrospectively evaluated. The Response Evaluation Criteria in Solid Tumors version 1.1 was applied to evaluate the treatment response. The local tumor control duration, progression-free survival (PFS), and overall survival (OS) were estimated using the Kaplan-Meier analysis.Results: At 30 days after the last multimodal treatment, complete response, partial response, and stable disease were recorded in 1 (10%), 7 (70%), and 2 (20%) patients, respectively, for an objective response rate of 80% and a disease control rate of 100%. No patient experienced progressive disease. The median duration of local tumor control was 8.0 months (95% CI, 6.2-9.7 months). The median PFS and OS were 11.0 months (95% CI, 6.9-15.1 months) and 8.0 months (95% CI, 5.5-10.5 months), respectively. Two cases of Grade III adverse events related to medications were reported.Conclusions: Sintilimab combined with BAI/DEE-BACE for patients with advanced NSCLC appears to be safe and feasible. Compared with previous studies on BAI/DEE-BACE, the addition of immunotherapy may improve survival. [ABSTRACT FROM AUTHOR]

Donor-acceptor (D-A) diaryl maleimides have received widespread attention due to their outstanding aggregation-enhanced emissive (AEE) properties. Herein, we report a novel rectangular D-A conjugated macrocyclic tetramaleimide with two phenyl and two 2,7-pyrene moieties as the sidewalls, while the maleimides as four corner linkers via dynamic and reversible Perkin reactions under thermodynamic control. Due to the sensitive D-A conjugation effects resulted from the multipole moments by four maleimides, such unique macrocycle exhibits unusual solvatochromic luminescent properties with a typical D-A charge transfer (CT) emission feature in the polar solvents, but pyrene-like emission characteristics in the nonpolar solvents regardless of the concentrations. A novel rectangular D-A conjugated macrocyclic tetramaleimide has been synthesized via dynamic and reversible Perkin reactions, which exhibits unusual solvatochromic luminescent properties. [Display omitted] • A facile synthetic pathway for rectangular D-A conjugated macrocyclic maleimides have been developed. • Dynamic covalent Perkin reactions have been demostrated to be an efficient synthetic pathway for macrocyclic maleimides. • The obtained macrocyclic maleimides exhibit unexpected solvatochromic luminescent properties. • The obtained macrocyclic maleimides exhibit a typical D-A charge transfer (CT) emission feature in the polar solvents. • The obtained macrocyclic maleimides exhibit pyrene-like emssions in carbon tetrachloride. [ABSTRACT FROM AUTHOR]

This work demonstrates that the photoreduction of hexavalent chromium using iron-based metal organic framework was able to be enhanced through doping molybdenum disulfide. The 1.5 wt % molybdenum disulfide doped iron-based metal organic framework exhibited the best photocatalytic activity towards hexavalent chromium reduction with an efficiency of 98.8% over 60 min, accompanied by remarkable repeatability and stability. The enhancement of photocatalytic efficiency could be achieved by (i) relieving the recombination process of photogenerated carriers in iron-based metal organic framework resulting from the formation of heterojunction, (ii) reducing photogenerated electrons transfer resistance from the interior to the surface of iron-based metal organic framework because of favorable electron transfer of molybdenum disulfide, and (iii) regulating the positive charge distribution on the surface of iron-based metal organic framework. Importantly, nanosecond time-resolved transient absorption spectroscopy further disclosed that the doping of molybdenum disulfide fundamentally improved the utilization of photogenerated electrons. This work evidences the important role of heterojunction from a microscopic perspective, which provides inspiration for the preparation of highly-efficient environmental functional photocatalysts based on iron-based metal organic frameworks. [Display omitted] • Elegant visible-light-driven MoS 2 @Fe-MOF photocatalysts were fabricated. • Unique adsorption capacity of Cr(VI) was given as a prerequisite for photoreduction. • Accelerated Cr(VI) reduction was due to heterojunction and improved conductivity. • Nanosecond transient absorption spectroscopy proved heterojunction existence. [ABSTRACT FROM AUTHOR]